Histamine dihydrochloride in the management of acute myeloid leukaemia

Drugs

Volumn 71, Issue 1, 2011, Pages 109-122

  Yang, Lily P H ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTITRYPANOSOMAL AGENT; HISTAMINE; INTERLEUKIN 2; MONOAMINE OXIDASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASTHENIA; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; ENDOCARDITIS; EOSINOPHILIA; FATIGUE; FEVER; FLUSHING; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAND MAL EPILEPSY; GRANULOMA; HEADACHE; HEART PALPITATION; HEPATOBILIARY DISEASE; HUMAN; INJECTION SITE ERYTHEMA; KIDNEY CANCER; LEUKOPENIA; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; POLYARTHRITIS; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN THROMBOSIS; VOMITING;

CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; FEMALE; HISTAMINE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 78650959436     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206410-000000000-00000     Document Type: Article

References (59)

1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004, 98-117.
2. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010 Feb; 24 (1): 35-63.
3. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009 Jul 30; 114 (5): 937-51.
4. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia [published erratum appears in Mayo Clin Proc 2006 Apr; 81 (4): 569]. Mayo Clin Proc 2006 Feb; 81 (2): 247-60.
5. Gaidzik V, Dohner K. Prognostic implications of gene mu-tations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008 Aug; 35 (4): 346-55.
6. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007 Jan; 18 Suppl. 1:i3-8.
7. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology: acute myeloid leukemia (V.2.2011) [online]. Available from URL: http://www. nccn.org/professionals/physician-gls/PDF/aml.pdf [Accessed 2010 Dec 7].
8. Bhayat F, Das-Gupta E, Smith C, et al. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 2009 Jul 26; 9: 252.
9. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007: overview. US National Cancer Institute [online]. Available from URL: http://seer.cancer. gov/csr/1975-2007/results-merged/sect-01-overview.pdf [Accessed 2010 Sep 29].
10. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults: British Committee for Standards in Haematology. Br J Haematol 2006 Nov; 135 (4): 450-74.
11. Pulte D, Gondos A, Brenner H. Improvement in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008 Apr; 93 (4): 594-600.
12. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2010 May; 21 Suppl. 5: v158-61.
13. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review 1975-2007: leukemia. US National Cancer Institute [online]. Available from URL: http://seer.cancer. gov/csr/1975-2007/results-merged/sect-1 3-leukemia.pdf [Accessed 2010 Sep 29].
14. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31 Pt 2:2349-70.
15. Baer MR. Is there a role for maintenance therapy in acute myeloid leukaemia? Best Pract Res Clin Haematol 2009 Dec; 22 (4): 517-21.
16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published erratum appears in J Clin Oncol 2004 Feb 1; 22 (3): 576]. J Clin Oncol 2003 Dec 15; 21 (24): 4642-9.
17. Dohner H, Estey EH, Amadori S, et al. Diagnosis and man-agement of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010 Jan 21; 115 (3): 453-74.
18. Lancet JE, Karp JE. Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol 2009; 16 (2): 105-11.
19. Bubenk J. Interleukin-2 therapy of cancer. Folia Biol (Praha) 2004; 50 (3-4): 120-30.
20. Martner A, Thoren FB, Aurelius J, et al. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Exp Rev Hematol 2010 Aug; 3 (4): 381-97.
21. Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 2008 Sep; 142 (6): 877-88.
22. Waldmann TA. The biology of interleukin-2 and interleu-kin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006 Aug; 6 (8): 595-601.
23. Eklund JW, KuzelTM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004 Nov; 16 (6): 542-6.
24. Novartis Pharmaceuticals Corporation. Proleukin® (alde-sleukin): US prescribing information [online]. Available from URL: http://www.proleukin.com/ assets/pdf/proleukin. pdf [Accessed 2010 Dec 7].
25. 6IU (aldesleukin) powder for solution for injection or infusion: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/ medicine/ 19322/SPC/Proleukin/ [Accessed 2010 Dec 7].
26. Blaise D, Attal M, Reiffers J, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000 Mar; 11 (1): 91-8.
27. Kolitz JE, Hars V, DeAngelo DJ, et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients <60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808 [abstract no. 157]. Blood 2007 Nov 16; 110 (11): e157.
28. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood 2008 Feb 1; 111 (3): 1044-53.
29. Baer MR, George SL, Caligiuri MA, et al. Low-dose inter-leukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leuke-mia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008 Oct 20; 26 (30): 4934-9.
30. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recom-binant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010 Feb 10; 28 (5): 808-14.
31. Hellstrand K. Histamine in cancer immunotherapy: a pre-clinical background. Semin Oncol 2002 Jun; 29 (3 Suppl. 7): 35-40.
32. Murdoch C, Giannoudis A, Lewis CE. Mechanisms reg-ulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004 Oct 15; 104 (8): 2224-34.
33. Romero AI, Thoren FB, Aurelius J, et al. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009 Sep; 70 (3): 194-205.
34. EpiCept GmbH. Ceplene 0.5 mg/0.5 mL solution for injec-tion: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/ document-library/EPAR-Product-Information/human/ 000796/WC500023116.pdf [Accessed 2010 Dec 7].
35. European Medicines Agency. Ceplene: European public as-sessment report [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document- library/EPAR-Public-assessment-report/human/000796/WC500023115. pdf [Accessed 2010 Dec 7].
36. Jutel M, Akdis M, Akdis CA. Histamine, histamine recep-tors and their role in immune pathology. Clin Exp Allergy 2009 Dec; 39 (12): 1786-800.
37. Brune M, Hansson M, Mellqvist UH, et al. NK cell-medi-ated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996 Oct; 57 (4): 312-9.
38. Hellstrand K, Hermodsson S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol 1986 Jul 15; 137 (2): 656-60.
39. Hellstrand K, Asea A, Dahlgren C, et al. Histaminergic regulation of NK cells: role of monocyte-derived reactive oxygen metabolites. J Immunol 1994 Dec 1; 153 (11): 4940-7.
40. Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol 1990 Dec 15; 145 (12): 4365-70.
41. Asea A, Hermodsson S, Hellstrand K. Histaminergic reg-ulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 1996 Jan; 43 (1): 9-15.
42. Johansson S, Landstrom M, Hellstrand K, et al. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, hista-mine and radiation. Br J Cancer 1998 Apr; 77 (8): 1213-9.
43. Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996 Mar; 92 (3): 620-6.
44. Hellstrand K, Mellqvist U-H, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma 1997 Nov; 27 (5-6): 429-38.
45. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute mye-loid leukemia: results of a randomized phase 3 trial. Blood 2006 Jul 1; 108 (1): 88-96.
46. Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. Biodrugs 2000; 14 (5): 299-318.
47. Middleton M, Sarno M, Agarwala SS, et al. Pharmaco-kinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immuno-therapy with interleukin-2. J Clin Pharmacol 2002 Jul; 42 (7): 774-81.
48. Brune ML, Rowe JM, Szer J, et al. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML: long term follow-up of leukemia-free survival and overall survival [abstract no. 1846]. Blood 2007 Nov 16; 110 (11): 1846. Plus poster presented at the American Society of Hematology 49th Annual Meeting and Exposition; 2007 Dec 8-11; Atlanta (GA).
49. Brune L, Rowe JM, Buyse ME, et al. Six-year outcomes update from a randomized phase 3 trial in AML: durable effect of remission maintenance immunotherapy with his-tamine dihydrochloride and low-dose IL-2 [abstract no. 0845]. Haematologica 2009 Jun; 94 Suppl. 2: 340-1.
50. Buyse ME, Squifflet P, Allard SE, et al. Leukemia-free sur-vival (LFS) as a surrogate for overall survival (OS) in AML patients in remission: a trial of a novel immunotherapy with histamine dihydrochloride plus low-dose IL-2 (HDC/IL-2) [abstract no. 0519]. Haematologica 2008 Jul; 93 Suppl. 1: 209-10. Plus poster presented at the 13th Congress of the European Hematology Association; 2008 Jun 12-15; Copenhagen.
51. Wallhult A, Whisnant K, Nilsson I, et al. Quality-of-life during remission maintenance immunotherapy in AML: a prospective assessment using EORTC QLQ-C30 in a randomized trial of histamine dihydrochloride plus low-dose IL-2 (HDC/IL-2) [abstract no. 0794]. Haematologica 2008 Jul; 93 Suppl. 1: 316-7. Plus poster presented at the 13th Congress of the European Hematology Association; 2008 Jun 12-15; Copenhagen.
52. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cyto-genetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002 Dec 15; 100 (13): 4325-36.
53. Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cy-tarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and once course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia: a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003 Dec 15; 21 (24): 4496-504.
54. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cyto-genetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006 Jul 1; 108 (1): 63-73.
55. Swedish AML Group. National guidelines for diagnosis and treatment of acute myeloid leukemia in adults [in Swedish] [online]. Available from URL: http://www.sfhem.se/content/ download/2608/41988/file/AML-riktlinjer-uppdat- 100118.pdf [Accessed 2010 Aug 6].
56. EpiCept Corporation. EpiCept Corporation receives refusal to file letter from US FDA on Ceplene New Drug Application [online]. Available from URL: http://epct.client. shareholder.com/releasedetail.cfm?ReleaseID=501453 [Accessed 2010 Sep 28].
57. Barrett AJ, Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 2010 Aug; 161 (2): 223-32.
58. Mandelli F, Capria S, Vignetti M, et al. Use of interleukin-2 in the management of haematological malignancies: focus on minimal residual disease. Biodrugs 1999; 12 (1): 43-53.
59. Magar RS, Purdy C, Hayward A, et al. Cost-effectiveness analysis of histamine dihydrochloride +low dose interleu-kin-2 vs standard of care for acute myeloid leukemia patients in their first complete remission: a UK perspective [abstract no. PCN83]. Value Health 2009 Oct; 12 (7): A272. Plus poster presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris